Grandfield & Dodd LLC Grows Holdings in Genmab A/S (NASDAQ:GMAB)

Grandfield & Dodd LLC raised its position in Genmab A/S (NASDAQ:GMABFree Report) by 2.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,558 shares of the company’s stock after buying an additional 565 shares during the period. Grandfield & Dodd LLC’s holdings in Genmab A/S were worth $814,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of GMAB. Rockefeller Capital Management L.P. increased its position in shares of Genmab A/S by 1.7% during the first quarter. Rockefeller Capital Management L.P. now owns 18,508 shares of the company’s stock valued at $698,000 after acquiring an additional 310 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Genmab A/S by 5.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 6,268 shares of the company’s stock valued at $221,000 after purchasing an additional 337 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Genmab A/S by 1.0% during the 2nd quarter. Geode Capital Management LLC now owns 41,715 shares of the company’s stock worth $1,586,000 after purchasing an additional 408 shares during the period. HBK Sorce Advisory LLC boosted its holdings in shares of Genmab A/S by 4.8% in the 3rd quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company’s stock worth $322,000 after buying an additional 419 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Genmab A/S by 86.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock valued at $38,000 after buying an additional 498 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

Shares of GMAB stock opened at $28.70 on Friday. The stock has a market capitalization of $18.98 billion, a price-to-earnings ratio of 29.90, a PEG ratio of 2.06 and a beta of 0.99. The company’s fifty day simple moving average is $29.38 and its two-hundred day simple moving average is $30.27. Genmab A/S has a 1 year low of $26.32 and a 1 year high of $42.72.

Genmab A/S (NASDAQ:GMABGet Free Report) last released its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The company had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million. Equities research analysts anticipate that Genmab A/S will post 1.06 EPS for the current year.

Wall Street Analysts Forecast Growth

GMAB has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Thursday, April 4th. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $46.00 to $48.00 in a report on Friday, February 23rd. Morgan Stanley reissued an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. Citigroup downgraded Genmab A/S from a “neutral” rating to a “sell” rating in a research report on Monday, January 22nd. Finally, Truist Financial reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Tuesday, March 26th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $48.50.

View Our Latest Research Report on Genmab A/S

Genmab A/S Profile

(Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Further Reading

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMABFree Report).

Institutional Ownership by Quarter for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.